Barbara J McCarson

Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults

P. van Damme, T. Vesikari, J. Boslego, 2007, Human vaccines.

Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.

S. Halperin, F. Diaz-Mitoma, D. Radley, 2009, Vaccine.

Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine

K. Schmader, M. Levin, Z. Popmihajlov, 2018, The Journal of infectious diseases.

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.

K. Reisinger, J. Stek, F. Schödel, 2012, Vaccine.